Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/27/2005US20050238660 Cpg formulations and related methods
10/27/2005US20050238651 Treatment of inflammatory bowel disease
10/27/2005US20050238638 Dietary Supplement that Serves as a Carbohydrate Blocker and Hangover Remedy
10/27/2005US20050238634 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
10/27/2005US20050238618 Low molecular weight polymers
10/27/2005US20050238616 Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
10/27/2005US20050238615 Process for the production of dendritic trimesic acid triamides
10/27/2005US20050238614 Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
10/27/2005US20050238609 Cubic gel particles, uses thereof
10/27/2005US20050238602 Mixture of water soluble zinc salts, farnesol, panthenol and quaternary ammonium compound; surgical hand wash
10/27/2005US20050238589 Methods and compositions for preventing or treating periodontal diseases
10/27/2005US20050238578 Administering anticarcinogenic agent and chelate complex of macrocyclic aminophosphonic acid and radionuclide such as samarium ethylenediaminetetramethylenephosphonic acid (EDTMP) to replace total body irradiation;antiproliferative agents; autoimmune, infectious, metabolic or genetic disorders
10/27/2005US20050236328 Chitosan-containing polysaccharide, method for preparing the same and use thereof
10/27/2005US20050235432 Composition for dyeing keratin fibers, comprising at least one alcohol oxidase, at least one oxidation dye precursor, and at least one azo, methine or azomethine cationic direct dye, and process using this composition
10/27/2005DE202005013839U1 Tablet containing monobasic acid salt of clopidogrel, useful for preventing thromboembolic events, e.g. stroke or myocardial infarction, contains no ionic or basic auxiliaries or polyethylene glycol
10/27/2005DE102004018794A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
10/27/2005DE102004017739A1 New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis
10/27/2005DE102004017627A1 Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression Full use of 5-HT1A agonists to inhibit opiate / opioid-induced respiratory depression
10/27/2005DE102004009076A1 Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel Alkyl carbamate-substituted β-lactones, processes and intermediates for their preparation containing these compounds and pharmaceutical
10/27/2005DE10117834B4 Verwendung von Phosphotyrosin zum Schutz von biologischem Material sowie kosmetische Zusammensetzung und Kultivierungsmedium Use of phosphotyrosine on the protection of biological material and cosmetic composition and culture medium
10/27/2005CA2575602A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
10/27/2005CA2569007A1 Crystalline 2-amino-3-cyanoquinoline derivatives, process of their preparation and pharmaceutical compositions containing them
10/27/2005CA2564878A1 Therapeutic heparins and their binding to interleukins 4 and 5, and pecam-1
10/27/2005CA2564811A1 Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
10/27/2005CA2563689A1 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
10/27/2005CA2563544A1 Lung surfactant supplements
10/27/2005CA2563386A1 Selected cgrp-antagonists, their preparation processes and their use as medicaments
10/27/2005CA2563291A1 4-cyano-phenoxy-alkyl carboxyl derivatives as androgen modulators
10/27/2005CA2563104A1 Association between a heterocyclic compound and an antioxidant agent and pharmaceutical compositions containing them
10/27/2005CA2563010A1 Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
10/27/2005CA2562937A1 Use of peptidic compounds for the prophylaxis and treatment of chronic headache
10/27/2005CA2562846A1 Sulphur-linked imidazole compounds for the treament of hiv
10/27/2005CA2562844A1 Process for forming amorphous atorvastatin calcium
10/27/2005CA2562827A1 Thienopyridine derivatives
10/27/2005CA2562699A1 Systems and methods for improving image-guided tissue ablation
10/27/2005CA2562694A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005CA2562619A1 Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
10/27/2005CA2562617A1 (poly)aminoalkylaminoacetamide derivatives of epipodophyllotoxin, their process of preparation and their applications in therapeutics as anticancer agents
10/27/2005CA2562614A1 Use of treprostinil to treat neuropathic diabetic foot ulcers
10/27/2005CA2562602A1 2-aminopyridine derivative
10/27/2005CA2562554A1 Thio-substituted arylmethanesulfinyl derivatives
10/27/2005CA2562529A1 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
10/27/2005CA2562526A1 Selected cgrp antagonists, method for producing the same and the use thereof as drugs
10/27/2005CA2562473A1 Preventive and/or therapeutic agent for inflammatory bowel diseases
10/27/2005CA2562465A1 R(-)-11-hydroxyaporphine derivatives and uses thereof
10/27/2005CA2562406A1 Cyclic amine compound
10/27/2005CA2562401A1 Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
10/27/2005CA2562391A1 Solid pharmaceutical preparation
10/27/2005CA2562369A1 Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
10/27/2005CA2562356A1 Treatment of ophthalmic conditions with mineralcorticoids
10/27/2005CA2562277A1 Methods of using sustained release aminopyridine compositions
10/27/2005CA2562244A1 Cyclic compounds
10/27/2005CA2562242A1 Polycylic thiazoles as potassium ion channel modulators
10/27/2005CA2562235A1 Piperazinylpiperidine derivatives as chemokine receptor antagonists
10/27/2005CA2562138A1 Fused ring nk1 antagonists
10/27/2005CA2562132A1 17 beta-acetamide-4-azasteroids as androgen receptor modulators
10/27/2005CA2562078A1 Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
10/27/2005CA2562069A1 Therapeutic combination for treatment of alzheimers disease
10/27/2005CA2561904A1 Mitotic kinesin inhibitors
10/27/2005CA2561895A1 Polycyclic pyrimidines as potassium ion channel modulators
10/27/2005CA2561718A1 Polycyclic pyridines as potassium ion channel modulators
10/27/2005CA2561680A1 Macular edema patient selection method and treatment with eye implant comprising a steroid
10/27/2005CA2561564A1 Pgd2 receptor antagonists for the treatment of inflammatory diseases
10/27/2005CA2561555A1 Bicyclic aromatic sulfinyl derivatives
10/27/2005CA2561364A1 Steroid sparing agents and methods of using same
10/27/2005CA2561348A1 Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use
10/27/2005CA2561315A1 Inhibitors of akt activity
10/27/2005CA2561311A1 Inhibitors of akt activity
10/27/2005CA2561296A1 Crystalline polymorph of bazedoxifene acetate
10/27/2005CA2561124A1 Bazedoxifene acetate solid dispersion formulations
10/27/2005CA2561014A1 Thioamide derivatives as progesterone receptor modulators
10/27/2005CA2561010A1 Crystalline polymorph of bazedoxifene acetate
10/27/2005CA2561004A1 Bazedoxifene ascorbate as selective estrogen receptor modulator
10/27/2005CA2560997A1 Delayed release formulations of 6-mercaptopurine
10/27/2005CA2560654A1 Imroved formulations of 6-mercaptopurine
10/27/2005CA2560346A1 Polycyclic pyridines as potassium ion channel modulators
10/27/2005CA2560336A1 Benzofuranyl derivatives useful for the treatment of cardiac arrhythmia
10/27/2005CA2559698A1 Novel alkyne compounds exhibiting an mch antagonistic effect and drugs containing said compounds
10/27/2005CA2559568A1 Materials and methods for treating coagulation disorders
10/27/2005CA2558331A1 Use of a pyrazole derivative for producing medicaments that are useful in preventing and treating chronic bronchitis and chronic obstructive bronchopneumopathy
10/27/2005CA2557852A1 Substituted cinnolin-4-ylamines
10/27/2005CA2505469A1 Drug delivery device comprising a bilayered polymeric coating having a cell cycle inhibitor that acts selectively at the g1 phase of the cell cycle incorporated into the first polymer coating layer
10/27/2005CA2503554A1 Dietary supplement
10/26/2005EP1589115A2 Polymorphisms of the human organic anion transporting polypeptide-C (OATP-C)
10/26/2005EP1589036A1 Amides of hyaluronic acid and the derivatives thereof
10/26/2005EP1589031A2 Production of polyketides and other natural products
10/26/2005EP1589028A2 Modified oligonucleotides, their preparation and their use
10/26/2005EP1589023A1 Oligosaccharide derivative
10/26/2005EP1589017A2 12,13-modified epothilone derivatives
10/26/2005EP1589016A1 Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
10/26/2005EP1589013A2 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/26/2005EP1589010A1 New C-Glycoside derivatives and uses thereof
10/26/2005EP1589008A1 A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
10/26/2005EP1589007A2 5-membered heterocycle derivatives, production thereof and their use as medicaments
10/26/2005EP1589006A1 Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents
10/26/2005EP1589005A1 Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts
10/26/2005EP1589004A1 Alkaloid compounds and their use as anti-malarial drugs
10/26/2005EP1589000A2 (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
10/26/2005EP1588739A1 Composition comprising a combination of calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
10/26/2005EP1588727A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
1 ... 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 ... 7860